Replies to post #1805 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Lovenox is not a competitor of ATryn.

>Isn't Lovenox a direct factor Xa inhibitor of some sorts?<

Yes. Thrombin catalyzes the conversion of FV to FVa and FVIII to FVIIIa, which creates a feedback loop though FXa that greatly accelerates the production of more thrombin. (This feedback loop is omitted from the diagram in #msg-14675390 for simplicity.) By inhibiting FXa, Lovenox diminishes the feedback effect.

LMW heparins such as Lovenox also inhibit thrombin directly, but they do this weakly compared to the AT-heparin complex.

Because they lack strong direct anti-thrombin activity, LMW heparins such as Lovenox are less effective than unfractionated heparin or synthetic direct thrombin inhibitors in most acute indications, and they would not be the drugs of choice in DIC.

>If Atryn is to succeed in non-HD indications its anti-inflammatory properties will need to shine through.<

As shown in the diagram in #msg-14516396, both anti-inflammatory and anti-thrombin activity are important in stopping the cascade responsible for DIC in sepsis.